Vaxcyte reported positive Phase 3 OPUS-1 results for VAX-31, meeting all endpoints. The company also announced $500M stock/warrant and $500M convertible note offerings to fund development and commercial prep.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
